97 related articles for article (PubMed ID: 22002543)
1. Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study.
Gross ME; Leichman L; Lowe ES; Swaisland A; Agus DB
Cancer Chemother Pharmacol; 2012 Jan; 69(1):273-80. PubMed ID: 22002543
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study.
Daw NC; Furman WL; Stewart CF; Iacono LC; Krailo M; Bernstein ML; Dancey JE; Speights RA; Blaney SM; Croop JM; Reaman GH; Adamson PC;
J Clin Oncol; 2005 Sep; 23(25):6172-80. PubMed ID: 16135484
[TBL] [Abstract][Full Text] [Related]
3. Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.
Baselga J; Cervantes A; Martinelli E; Chirivella I; Hoekman K; Hurwitz HI; Jodrell DI; Hamberg P; Casado E; Elvin P; Swaisland A; Iacona R; Tabernero J
Clin Cancer Res; 2010 Oct; 16(19):4876-83. PubMed ID: 20805299
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors.
Drevs J; Siegert P; Medinger M; Mross K; Strecker R; Zirrgiebel U; Harder J; Blum H; Robertson J; Jürgensmeier JM; Puchalski TA; Young H; Saunders O; Unger C
J Clin Oncol; 2007 Jul; 25(21):3045-54. PubMed ID: 17634482
[TBL] [Abstract][Full Text] [Related]
5. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.
Burris HA; Hurwitz HI; Dees EC; Dowlati A; Blackwell KL; O'Neil B; Marcom PK; Ellis MJ; Overmoyer B; Jones SF; Harris JL; Smith DA; Koch KM; Stead A; Mangum S; Spector NL
J Clin Oncol; 2005 Aug; 23(23):5305-13. PubMed ID: 15955900
[TBL] [Abstract][Full Text] [Related]
6. A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors.
Fakih MG; Trump DL; Muindi JR; Black JD; Bernardi RJ; Creaven PJ; Schwartz J; Brattain MG; Hutson A; French R; Johnson CS
Clin Cancer Res; 2007 Feb; 13(4):1216-23. PubMed ID: 17317832
[TBL] [Abstract][Full Text] [Related]
7. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
Herbst RS; Maddox AM; Rothenberg ML; Small EJ; Rubin EH; Baselga J; Rojo F; Hong WK; Swaisland H; Averbuch SD; Ochs J; LoRusso PM
J Clin Oncol; 2002 Sep; 20(18):3815-25. PubMed ID: 12228201
[TBL] [Abstract][Full Text] [Related]
8. First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors.
Munster PN; Britten CD; Mita M; Gelmon K; Minton SE; Moulder S; Slamon DJ; Guo F; Letrent SP; Denis L; Tolcher AW
Clin Cancer Res; 2007 Feb; 13(4):1238-45. PubMed ID: 17317835
[TBL] [Abstract][Full Text] [Related]
9. Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.
Simonelli M; Zucali PA; Lorenzi E; Rubino L; De Vincenzo F; De Sanctis R; Perrino M; Mancini L; Di Tommaso L; Rimassa L; Masci G; Zuradelli M; Suter MB; Bertossi M; Fattuzzo G; Giordano L; Roncalli MG; Santoro A
Eur J Cancer; 2013 Mar; 49(5):989-98. PubMed ID: 23146956
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations.
Dees EC; Cohen RB; von Mehren M; Stinchcombe TE; Liu H; Venkatakrishnan K; Manfredi M; Fingert H; Burris HA; Infante JR
Clin Cancer Res; 2012 Sep; 18(17):4775-84. PubMed ID: 22767670
[TBL] [Abstract][Full Text] [Related]
11. Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours.
van Cruijsen H; Voest EE; Punt CJ; Hoekman K; Witteveen PO; Meijerink MR; Puchalski TA; Robertson J; Saunders O; Jürgensmeier JM; van Herpen CM; Giaccone G
Eur J Cancer; 2010 Mar; 46(5):901-11. PubMed ID: 20061136
[TBL] [Abstract][Full Text] [Related]
12. Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors.
Demetri GD; Lo Russo P; MacPherson IR; Wang D; Morgan JA; Brunton VG; Paliwal P; Agrawal S; Voi M; Evans TR
Clin Cancer Res; 2009 Oct; 15(19):6232-40. PubMed ID: 19789325
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours.
de Jonge MJ; Dumez H; Verweij J; Yarkoni S; Snyder D; Lacombe D; Marréaud S; Yamaguchi T; Punt CJ; van Oosterom A;
Eur J Cancer; 2006 Aug; 42(12):1768-74. PubMed ID: 16815702
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer.
Adjei AA; Molina JR; Mandrekar SJ; Marks R; Reid JR; Croghan G; Hanson LJ; Jett JR; Xia C; Lathia C; Simantov R
Clin Cancer Res; 2007 May; 13(9):2684-91. PubMed ID: 17473200
[TBL] [Abstract][Full Text] [Related]
15. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors.
Nakagawa K; Tamura T; Negoro S; Kudoh S; Yamamoto N; Yamamoto N; Takeda K; Swaisland H; Nakatani I; Hirose M; Dong RP; Fukuoka M
Ann Oncol; 2003 Jun; 14(6):922-30. PubMed ID: 12796031
[TBL] [Abstract][Full Text] [Related]
16. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors.
Pardo B; Paz-Ares L; Tabernero J; Ciruelos E; García M; Salazar R; López A; Blanco M; Nieto A; Jimeno J; Izquierdo MA; Trigo JM
Clin Cancer Res; 2008 Feb; 14(4):1116-23. PubMed ID: 18281545
[TBL] [Abstract][Full Text] [Related]
18. Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy.
Wolf M; Swaisland H; Averbuch S
Clin Cancer Res; 2004 Jul; 10(14):4607-13. PubMed ID: 15269131
[TBL] [Abstract][Full Text] [Related]
19. Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors.
Yamamoto N; Tamura T; Yamamoto N; Yamada K; Yamada Y; Nokihara H; Fujiwara Y; Takahashi T; Murakami H; Boku N; Yamazaki K; Puchalski TA; Shin E
Cancer Chemother Pharmacol; 2009 Nov; 64(6):1165-72. PubMed ID: 19308410
[TBL] [Abstract][Full Text] [Related]
20. A pilot trial of gefitinib in combination with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer.
Manegold C; Gatzemeier U; Buchholz E; Smith RP; Fandi A
Clin Lung Cancer; 2005 May; 6(6):343-9. PubMed ID: 15943894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
